Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (k562/dox) cells

Cellular and Molecular Biology

Volumn 61, Issue 8, 2015, Pages 118-122

  Yousefi, B ^a,b   Samadi, Nasser ^a,b   Baradaran, B ^a   Rameshknia, V ^a   Shafiei Irannejad, V ^b   Majidinia, M ^b   Targhaze, N ^a   Zarghami, Nosratollah ^b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiotoxicity; Chronic myeloid leukemia; Doxorubicin; Multidrug resistance; P glycoprotein; PPAR

Indexed keywords

ALEGLITAZAR; DOXORUBICIN; FENOFIBRATE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; CHROMAN DERIVATIVE; OXAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; K562 CELL LINE; MTT ASSAY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FENOFIBRATE; GENE EXPRESSION; HUMANS; K562 CELLS; OXAZOLES; P-GLYCOPROTEIN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RHODAMINE 123; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; THIOPHENES;

EID: 84962175456     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2015.61.8.19     Document Type: Article

References (27)

1. Holohan C., Van Schaeybroeck S., Longley D. B., and Johnston P. G. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013, 13(10):714-726, doi: 10.1038/nrc3599.
2. Saraswathy M. and Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv. 2013, 31(8):1397-1407, doi: 10.1016/j.biotechadv.2013.06.004.
3. Szakács G., Paterson J. K., Ludwig J. A., Booth-Genthe C., and Gottesman M. M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006, 5(3):219-234, doi: 10.1038/nrd1984
4. Yousefi B., Samadi N., and Ahmadi Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair (Amst). 2014, 22:24-9, doi: 0.1016/j.dnarep.2014.07.001.
5. Gottesman M. M., Fojo T., and Bates S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002, 2(1):48-58, doi: 10.1038/nrc706.
6. Mohammadzadeh R, Baradaran B, Valizadeh H, Yousefi B, Zakeri-Milani P. Reduced ABCB1 Expression and Activity in the Presence of Acrylic Copolymers. Adv Pharm Bull. 2014, 4(3):219-24, doi: 0.5681/apb.2014.032.
7. Montazami N., Kheir Andish M., Majidi J., Yousefi M., Yousefi B., Mohamadnejad L., Shanebandi D., Estiar M. A., Khaze V., Mansoori B., Baghbani E., and Baradaran B. siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells. Cell Mol Biol (Noisy-le-grand). 2015, 61(2):98-103.
8. Kim R. B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002, 34(1-2):47-54, doi: 10.1081/DMR-120001389.
9. Aller S. G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P. M., Trinh Y. T., Zhang Q., and Urbatsch I. L. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009, 323(5922):1718-1722, doi: 10.1126/science.1168750.
10. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., and O'Rahilly S. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006, 58(4):726-741, doi: 10.1081/DMR-120001389.
11. Michalik L., Desvergne B., and Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004, 4(1):61-70, doi: 10.1038/nrc1254.
12. Charkhpour M., Ghavimi H., Ghanbarzadeh S., Yousefi B., Khorrami A., Mesgari M., and Hassanzadeh K. Protective effect of pioglitazone on morphine-induced neuroinflammation in the rat lumbar spinal cord. J Biomed Sci. 2015, 22(1):82, doi: 10.1186/s12929-015-0187-2.
13. Keshamouni V. G., Reddy R. C., Arenberg D. A., Joel B., Thannickal V. J., Kalemkerian G. P., and Standiford T. J. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene. 2004, 23(1):100-108, doi: 10.1038/sj.onc.1206885.
14. Yousefi B, Darabi M, Baradaran B, Shekari Khaniani M, Rahbani M, Darabi M, Fayezi S, Mehdizadeh A, Saliani N, Shaaker M. Inhibition of MEK/ERK1/2 Signaling Affects the Fatty Acid Composition of HepG2 Human Hepatic Cell Line. Bioimpacts. 2012, 2(3):145-50. doi: 5681/bi.2012.019.
15. Peters J. M., Shah Y. M., and Gonzalez F. J. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012, 12(3):181-195, doi: 10.1038/nrc3214.
16. Ghanbari P., Mohseni M., Tabasinezhad M., Yousefi B., Saei A. A., Sharifi S., Rashidi M. R., and Samadi N. Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol. 2014, 174(2):667-681, doi: 10.1007/s12010-014-1125-6
17. Nobili S., Landini I., Mazzei T., and Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 2012, 32(6):1220-1262, doi: 10.1002/med.20239.
18. Binkhathlan Z. and Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013, 13(3):326-346.
19. Valentiner U., Carlsson M., Erttmann R., Hildebrandt H., and Schumacher U. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology. 2005, 213(1-2):157-68.
20. Ferruzzi P., Ceni E., Tarocchi M., Grappone C., Milani S., Galli A., Fiorelli G., Serio M., and Mannelli M. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab. 2005, 90(3):1332-9, doi: http://dx.doi.org/10.1210/jc.2004-0978.
21. Bovelli D., Plataniotis G., and Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010, 21 (5): 277-82, doi: 10.1093/annonc/mdq200.
22. Octavia Y., Tocchetti C. G., Gabrielson K. L., Janssens S., Crijns H. J., and Moens A. L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012, 52(6):1213-25, doi: 10.1016/j.yjmcc.2012.03.006.
23. Cavender M. A. and Lincoff A. M. Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010, 10(4):209-16, doi: 10.2165/11539500-000000000-00000.
24. Davies G. F., Juurlink B. H., and Harkness T. A. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther. 2009, 3(79-88, doi: 10.1038/nature15248.
25. Zhang H., Jing X., Wu X., Hu J., Zhang X., Wang X., Su P., Li W., and Zhou G. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes. Anti-cancer drugs. 2015, 26(7):706-715, doi: 10.1097/CAD.0000000000000236.
26. Yousefi B, Rahmati M, Ahmadi Y. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci. 2014, 99(1-2):14-7. doi: 10.1016/j.lfs.2014.01.063.
27. Prost S., Relouzat F., Spentchian M., Ouzegdouh Y., Saliba J., Massonnet G., Beressi J.-P., Verhoeyen E., Raggueneau V., and Maneglier B. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR [ggr] agonists. Nature. 2015, doi: 10.1038/na15248.